Modern antibacterial therapy of respiratory infections: is there any hope?
A.A. Vizel, I.Yu. Vizel
Kazan State Medical University
Nowadays, the world community is concerned about the widespread increase in the resistance of clinically significant pathogenic microflora and the lack of revolutionary discoveries in creating new groups of antibacterial agents. The increase in antibiotic resistance occurs in the setting of new systemic antibacterial drugs deficiency. In recent decades, antibiotics development has slowed significantly С many pharmaceutical companies have stopped working in this area due to the clinical trials complexity and limited economic attractiveness of developing new antibiotics. Despite the fact that there is an increase in respiratory pathogens resistance to antibiotics of many pharmacological groups (both in the world and in Russia), amoxicillin/clavulanate still retains high antibacterial activity against all the respiratory infections main pathogens. Amoxicillin/clavulanate is recommended for lower respiratory tract infections treatment in adults and children and included in the national clinical guidelines for the treatment of community-acquired pneumonia and chronic obstructive pulmonary disease: for oral administration С at the outpatient treatment stage, for parenteral administration С in a clinical setting. One of the factors for the successful amoxicillin/clavulanate application is the presence of various dosage forms for enteral and parenteral administration, including soluble forms that improve pharmacokinetics and increase drug safety.
Keywords: respiratory infections, treatment, efficacy, safety, amoxicillin/clavulanate, Amoksiklav.
For citation: Vizel A.A., Vizel I.Yu. Modern antibacterial therapy of respiratory infections: is there any hope? RMJ. Medical Review. 2019;9(I):29-33.
2. Biedenbach D.J., Badal R.E., Huang M.Y. et al. In vitro activity of oral antimicrobial agents against pathogens associated with community-acquired upper respiratory tract and urinary tract infections: a five country surveillance study. Infect. Dis. Ther. 2016;5(2):139–153. DOI: 10.1007/s40121-016-0112-3.
3. Шаймуратов Р.И., Лысенко Г.В., Визель А.А. Структурный анализ состояния пациентов, поступивших в стационары Республики Татарстан, со смертельным исходом от внебольничной пневмонии в 2012 году. Вестник современной клинической медицины. 2013;6(4):25–29. [Shaimuratov R.I., Lysenko G.V., Vizel A.A. Structural analysis of the condition of patients admitted to hospitals of the Republic of Tatarstan, with a fatal outcome from community-acquired pneumonia in 2012. Bulletin of modern clinical medicine. 2013;6(4):25–29 (in Russ.)].
4. Визель А.А., Лысенко Г.В. Особенности ведения больных внебольничной пневмонией в Республике Татарстан. Фарматека. 2014;15(288):31–34. [Vizel A.A., Lysenko G.V. Features of the management of patients with community-acquired pneumonia in the Republic of Tatarstan. Farmateka. 2014;15(288):31–34 (in Russ.)].
5. Кузьменков А.Ю., Трушин И.В., Авраменко А.А. и др. AMRmap: Интернет-платформа мониторинга антибиотикорезистентности. Клиническая микробиология и антимикробная химиотерапия. 2017;19(2):84–90. [Kuzmenkov A. Yu., Trushin I.V., Avramenko A.A., et al. AMRmap: Internet platform for monitoring antibiotic resistance. Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19 (2): 84–90. (in Russ.)].
6. Chambers H. Other beta-lactam antibiotics. In: Mandell G.L., Bennet J.E., Dolin R., editors. Principles and Practice of Infectious Diseases. Churchill Livingstone, 6th edition, 2004.
7. Bush K. Other b-lactam antibiotics. In: Finch R.G., Greenwood D., Norrby S.R., Whitley R.J., editors. Antibiotic and Chemotherapy. Anti-infective agent and their use in therapy. Churchill Livingstone, 8th edition. 2003.
8. Neu H.C., Wilson A.P.R., Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother. 1993;5:67–93.
9. Pérez-Deago B., Alonso-Porcel C., Elvira-Menendez C. et al. Epidemiology and management of community acquired pneumonia: more than 10 years experience. Semergen. 2018;44(6):389–394. DOI: 10.1016/j.semerg.2018.01.008.
10. Умирова А.А., Кабакова Т.И., Аджиенко В.Л. Оценка врачебных предпочтений при выборе лекарственных препаратов для лечения внебольничной пневмонии на примере Кабардино-Балкарской Республики. Современные проблемы науки и образования. 2015;2(2):514. [Umirova A.A., Kabakova T.I., Adzhienko V.L. Evaluation of medical preferences when choosing drugs for the treatment of community-acquired pneumonia on the example of the Kabardino-Balkarian Republic. Modern problems of science and education. 2015;2(2):514 (in Russ.)].
11. Волкова Ю.С., Слободенюк Е.В. Антимикробные препараты для системного применения на фармацевтическом рынке г. Хабаровска: фармакоэкономический анализ. Тихоокеанский медицинский журнал. 2014;2(56):35–37. [Volkova Yu.S., Slobodenyuk E.V. Antimicrobial drugs for systemic use in the pharmaceutical market in Khabarovsk: pharmacoeconomic analysis. Pacific Medical Journal. 2014;2(56):35–37 (in Russ.)].
12. Клинические рекомендации (проект). Внебольничная пневмония. РРО. МАКМАХ. (Электронный ресурс). URL: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/. Дата обращения: 25.07.2019 [Clinical recommendations (draft). Community-acquired pneumonia. RRO. MAX. (Electronic resource). URL: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/. Access date: 25.07.2019 (in Russ.)].
13. Синопальников А.И. Антибиотики и внебольничные инфекции нижних дыхательных путей. Кому? Какой? Фарматека. 2019;5:47–60. [Sinopalnikov A.I. Antibiotics and community-acquired infections of the lower respiratory tract. To whom? Which one? Farmateka. 2019;5:47–60 (in Russ.)].
14. Ленкова Н.И., Евдокимова С.А., Демченкова Е.Ю. Амоксиклав при лечении бронхолегочных инфекций. РМЖ. 2005;5:264–266 [Lenkova N.I., Evdokimova S.A., Demchenkova E. Yu. Amoxiclav in the treatment of bronchopulmonary infections. RMJ. 2005;5:264–266 (in Russ.)].
15. Viasus D., Simonetti A.F., Garcia-Vidal C. et al. Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. J. Antimicrob. Chemother. 2017;72(2):547–553. DOI: 10.1093/jac/dkw441.
16. Kouakou-Siransy G., Horo K., Effo E. et al. Pharmacotherapeutic aspect of antibiotic therapy during acute community-acquired pneumonia in adults at the University Hospital of Cocody (Abidjan). Int. J. Clin. Pharmacol. Ther. 2015;53(11):940–946. DOI: 10.5414/CP202349.
17. Razazi K., Mekontso Dessap A., Carteaux G. et al. Frequency, associated factors and outcome of multi-drug-resistant intensive care unit-acquired pneumonia among patients colonized with extended-spectrum β-lactamase-producing Enterobacteriaceae. Ann. Intensive Care. 2017;7(1):61. DOI: 10.1186/s13613-017-283-284.
18. Steurer J. Positive effect of amoxicillin/clavulanic acid for exacerbations of mild to moderate COPD. Praxis (Bern 1994). 2013;102(5):301–302. DOI: 10.1024/1661-8157/a001195.
19. Brusse-Keizer M., VanderValk P., Hendrix R. et al. Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbations. BMJ Open Respir Res. 2014;1(1): e000052. DOI: 10.1136/bmjresp-2014-000052.
20. Brusse-Keizer M., VanderValk P., van der Zanden R.W. et al. Amoxicillin concentrations in relation to beta-lactamase activity in sputum during exacerbations of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:455–461. DOI: 10.2147/COPD.S70355.
21. Nijdam L.C., Assink M.D., Kuijvenhoven J.C. et al. Safety and tolerability of nebulized amoxicillin-clavulanic acid in patients with COPD (STONAC 1 and STONAC 2). COPD. 2016;13(4):448–454. DOI: 10.3109/15412555.2015.1107893.
22. Хроническая обструктивная болезнь легких. РРО. (Электронный ресурс). URL: http://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf. Дата обращения: 20.07.2019. [Chronic obstructive pulmonary disease. RRO. (Electronic resource). URL: http://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf. Access date: 07.25.2019 (in Russ.)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
